Disclaimer: Due to limited expertise, errors are inevitable, and some information may not be the most up-to-date. Comments are welcome to point out any issues. This article is only an introduction to medical and health-related drugs, not a recommendation of treatment plans (if involved); this article does not constitute any investment advice.
On June 23, 2025, Carisma Therapeutics and OrthoCellix, a wholly-owned subsidiary of Ocugen, jointly announced: the two parties have reached a reverse merger agreement,The two companies will merge through an all-stock transaction, aiming to create a larger-scale company listed on NASDAQ.Late-Stage Regenerative Cell Therapy Company。
The transaction has been unanimously approved by the boards of both companies and is expected to be completedCompleted in the second half of 2025。Upon completion of the proposed transaction, Carisma Therapeutics is expected to be renamed OrthoCellix and trade on the Nasdaq Capital Market under the ticker symbol "OCLX."
OrthoCellix is a wholly-owned subsidiary of Ocugen.Ocugen is a clinical-stage company dedicated to developing regenerative cell therapies for orthopedic diseases. The merged company will focus on developing OrthoCellix's NeoCart® technology for the treatment of knee cartilage defects and plans to launch the FDA-approved NeoCart®.Phase 3 Clinical Trial。NeoCart® Autologous Cartilage Implant Technology aims to repair knee cartilage defects using the patient's own cells. This innovative platform integrates a reinforced 3D scaffold and patented bioprocessing technology to culture chondrocytes (cells responsible for maintaining cartilage health) and generate a structure similar to juvenile cartilage upon implantation. NeoCart® is expected to accelerate healing and reduce pain by constructing a functional joint surface that closely resembles natural tissue, helping patients return to normal activities while preventing complications associated with articular cartilage injuries.Previously, NeoCart® had received the Regenerative Medicine Advanced Therapy (RMAT) designation.Source of the image:Ocugen Official WebsiteAccording to the terms of the merger agreement, OrthoCellix will merge with a wholly-owned subsidiary of Carisma and continue as a wholly-owned subsidiary of Carisma. Carisma will issue its common stock to pre-merger shareholders of OrthoCellix as merger consideration in exchange for the cancellation of OrthoCellix's common stock. Carisma also expects to enter into a private placement financing subscription agreement with Ocugen and other specific investors. This agreement is expected to be completed simultaneously with the completion of the merger, enabling the combined company to complete the Phase III clinical trial of NeoCart® without additional cost or investment from Ocugen. Upon the completion of the proposed transaction, Carisma shareholders will receive contingent value rights, representing the right to receive certain payments from the proceeds related to Carisma’s pre-transaction legacy assets.The proposed transaction is completed and expected$25 Million Concurrent FinancingAfter taking effect, OrthoCellix shareholders and other concurrent financing participants are expected to hold approximately 90% of the shares in the merged company, while existing Carisma shareholders are expected to hold about 10% of the shares in the merged company (on a fully diluted basis).The merged company is expected to have after financingCash flow of $60 million to $65 million(Including existing resources), which can support company operations until the completion of the trial.Shankar Musunuri, Ph.D., Chairman, CEO, and Co-Founder of Ocugen, stated"We believe that the merger of OrthoCellix and Carisma will enable us to create a publicly traded company focused on the development of NeoCart®, creating value for Ocugen and Carisma shareholders while unlocking the true market potential of NeoCart®. We believe NeoCart® has tremendous potential to bring a truly transformative approach to cartilage repair. We established OrthoCellix and dedicated resources with the aim of bringing this revolutionary technology to patients in dire need of it."Steven Kelly, President and CEO of Carisma Therapeutics, Inc., stated"Carisma Therapeutics has evaluated a series of strategic options, and we believe this proposed transaction represents an opportunity to create significant value for shareholders. OrthoCellix, with its NeoCart® platform, focus on developing regenerative cell therapies, and an experienced management team, holds a strong market position in the merged company."Reference: Company Announcement-END-
Scan to register
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)